Gilead Viread approval
Executive Summary
FDA approves tenofovir Oct. 26 for treatment of HIV-1 infection when used in combination with other antiretroviral agents. Gilead expects Viread will be in pharmacies "within days." FDA's Antiviral Drugs Advisory Committee suggested Oct. 3 that use of Viread be limited to use in treatment-experienced patients (1"The Pink Sheet" Oct. 8, p. 30)
You may also be interested in...
Gilead Viread Use Beyond HIV Drug-Experienced Patients Questioned By Cmte
Gilead's HIV drug Viread could be limited to use in treatment-experienced patients, a majority of FDA's Antiviral Drugs Advisory Committee suggested Oct. 3.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials